Overview of antiviral drug candidates targeting coronaviral 3C‐like main proteases

Citations Over TimeTop 10% of 2021 papers

Abstract

Coronaviruses (CoVs) are positive single-stranded RNA viruses that cause severe respiratory syndromes in humans, including severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Coronavirus disease 2019 (COVID-19) caused by a novel severe acute respiratory syndrome CoV (SARS-CoV-2) at the end of 2019 became a global pandemic. The 3C-like cysteine protease (3CLpro) processes viral polyproteins to yield mature non-structural proteins, thus playing an important role in the CoV life cycle, and therefore is considered as a prominent target for antiviral drugs. To date, many 3CLpro inhibitors have been reported, and their molecular mechanisms have been illustrated. Here, we briefly introduce the structural features of 3CLpro of the human-related SARS-CoV, MERS-CoV and SARS-CoV-2, and explore the potency and mechanism of their cognate inhibitors. This information will shed light on the development and optimization of CoV 3CLpro inhibitors, which may benefit the further designation of therapeutic strategies for treating CoV diseases.

Related Papers

• → A clinician's guide to drug‐drug interactions with direct‐acting antiviral agents for the treatment of hepatitis C viral infection(2015)45 cited
• → Possible drug-drug interactions among elderly patients receiving antiviral therapy for chronic hepatitis B(2024)1 cited
• → On the use of PIPSA to Guide Target‐Selective Drug Design(2007)12 cited
• → Fluorescent drug analogs to study drug-target interactions in intact cells(2024)1 cited
• → Drug promiscuity: problems and promises(2023)3 cited